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less likely to receive antidepressant pharmacotherapy
(OR = 0.30, 95% CI = 0.16–0.56) and 80% less likely to
receive an SSRI or SNRI (OR = 0.20, 95% CI =
0.10–0.40) but nearly twice more likely to receive psy-
chotherapy (OR = 2.93, 95% CI = 1.44–5.94), compared
to patients covered by private insurance (67.6%). Patients
lived in the south were the least likely to receive antide-
pressant pharmacotherapy, an SSRI or SNRI and psy-
chotherapy, compared to other regions (northeast, west
and midwest). Other factors predictive of receipt antide-
pressant pharmacotherapy include patients 50 to 64 years
old (patients 30 to 49 as reference) and female gender.
Other factor predictive of receipt of psychotherapy
included self-report depression as a reason for ofﬁce visit
and duration of the encounter.
CONCLUSION: Among patients diagnosed with depres-
sion, factors affecting the pattern of prescribing antide-
pressant pharmacotherapy and psychotherapy include 
a patient’s age, gender, type of insurance coverage, self-
report of depression and region lived in. Further research
is required to discern the reasons for these observed
effects.
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Differences between Veterans Affairs (VA) and non-VA
Medicaid patients with schizophrenia may limit the
ability to generalize study results from one group to the
other.
OBJECTIVE: This study assessed the clinical compara-
bility of patients with schizophrenia in these two popu-
lations (VA and Non-VA Medicaid), after adjusting for
important background characteristics.
METHOD: Baseline data from the U.S Schizophrenia
Care and Assessment Program, (US-SCAP), a prospective,
naturalistic study of schizophrenia, with a total of 223
VA patients were matched with Non-VA Medicaid
patients (N = 1,428), using propensity scores calculated
based on patients’ characteristics (gender, age, race, age
at illness onset, and study site). Using standard measures,
the matched pairs (N = 217) were compared on 28 
parameters of clinical symptomatology, level of function-
ing, quality of life, alcohol and drug abuse, depression,
concurrent medical conditions, prior hospitalization,
medication adherence, and work status.
RESULTS: VA and Non-VA Medicaid patients did not
signiﬁcantly differ on 26 of the 28 studied parameters.
For two-thirds of the parameters, the magnitude of the
difference between the groups was less than 10%.
CONCLUSIONS: Current ﬁndings suggest clinical com-
parability of VA and Non-VA Medicaid patient groups,
with potential generalizeability of clinical ﬁndings from
one group to the other, after adjustments for background
characteristics.
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